NASDAQ:CODX

Co-Diagnostics Competitors

$9.10
-0.20 (-2.15 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.86
Now: $9.10
$9.27
50-Day Range
$8.52
MA: $12.75
$17.04
52-Week Range
$7.86
Now: $9.10
$30.99
Volume725,650 shs
Average Volume1.56 million shs
Market Capitalization$260.86 million
P/E Ratio11.23
Dividend YieldN/A
Beta-3.3

Competitors

Co-Diagnostics (NASDAQ:CODX) Vs. CERS, KIDS, ANGO, CRY, OFIX, and SRDX

Should you be buying CODX stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Co-Diagnostics, including Cerus (CERS), OrthoPediatrics (KIDS), AngioDynamics (ANGO), CryoLife (CRY), Orthofix Medical (OFIX), and Surmodics (SRDX).

Cerus (NASDAQ:CERS) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 27.1% of Co-Diagnostics shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cerus and Co-Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
Co-Diagnostics01102.50

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. Co-Diagnostics has a consensus target price of $18.00, suggesting a potential upside of 97.80%. Given Co-Diagnostics' higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Cerus.

Valuation and Earnings

This table compares Cerus and Co-Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million13.81$-71,240,000.00($0.51)-12.02
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28

Co-Diagnostics has lower revenue, but higher earnings than Cerus. Co-Diagnostics is trading at a lower price-to-earnings ratio than Cerus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -3.3, meaning that its stock price is 430% less volatile than the S&P 500.

Profitability

This table compares Cerus and Co-Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
Co-Diagnostics53.81%93.48%88.06%

Summary

Co-Diagnostics beats Cerus on 8 of the 14 factors compared between the two stocks.

Co-Diagnostics (NASDAQ:CODX) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Co-Diagnostics and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95

Co-Diagnostics has higher earnings, but lower revenue than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Co-Diagnostics and OrthoPediatrics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Co-Diagnostics01102.50
OrthoPediatrics00303.00

Co-Diagnostics currently has a consensus price target of $18.00, suggesting a potential upside of 97.80%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given Co-Diagnostics' higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than OrthoPediatrics.

Profitability

This table compares Co-Diagnostics and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Co-Diagnostics53.81%93.48%88.06%
OrthoPediatrics-34.26%-11.57%-8.79%

Institutional and Insider Ownership

27.1% of Co-Diagnostics shares are held by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Co-Diagnostics has a beta of -3.3, suggesting that its share price is 430% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Summary

Co-Diagnostics beats OrthoPediatrics on 8 of the 14 factors compared between the two stocks.

Co-Diagnostics (NASDAQ:CODX) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

27.1% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 94.9% of AngioDynamics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 3.8% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Co-Diagnostics and AngioDynamics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28
AngioDynamics$264.16 million3.43$-166,790,000.00$0.09264.11

Co-Diagnostics has higher earnings, but lower revenue than AngioDynamics. Co-Diagnostics is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Co-Diagnostics and AngioDynamics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Co-Diagnostics01102.50
AngioDynamics01102.50

Co-Diagnostics currently has a consensus price target of $18.00, suggesting a potential upside of 97.80%. AngioDynamics has a consensus price target of $24.00, suggesting a potential upside of 0.97%. Given Co-Diagnostics' higher possible upside, research analysts clearly believe Co-Diagnostics is more favorable than AngioDynamics.

Profitability

This table compares Co-Diagnostics and AngioDynamics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Co-Diagnostics53.81%93.48%88.06%
AngioDynamics-62.82%-0.12%-0.10%

Volatility and Risk

Co-Diagnostics has a beta of -3.3, indicating that its stock price is 430% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Summary

Co-Diagnostics beats AngioDynamics on 7 of the 12 factors compared between the two stocks.

Co-Diagnostics (NASDAQ:CODX) and CryoLife (NYSE:CRY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

27.1% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 80.9% of CryoLife shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Co-Diagnostics and CryoLife, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Co-Diagnostics01102.50
CryoLife00303.00

Co-Diagnostics currently has a consensus price target of $18.00, suggesting a potential upside of 97.80%. CryoLife has a consensus price target of $28.3333, suggesting a potential upside of 25.31%. Given Co-Diagnostics' higher possible upside, research analysts clearly believe Co-Diagnostics is more favorable than CryoLife.

Profitability

This table compares Co-Diagnostics and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Co-Diagnostics53.81%93.48%88.06%
CryoLife-5.45%1.86%0.82%

Valuation and Earnings

This table compares Co-Diagnostics and CryoLife's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28
CryoLife$276.22 million3.20$1.72 million$0.3172.94

CryoLife has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Co-Diagnostics has a beta of -3.3, indicating that its stock price is 430% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

CryoLife beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

Orthofix Medical (NASDAQ:OFIX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Orthofix Medical and Co-Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orthofix Medical$459.95 million1.82$-28,460,000.00$1.4729.16
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28

Co-Diagnostics has lower revenue, but higher earnings than Orthofix Medical. Co-Diagnostics is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

93.9% of Orthofix Medical shares are owned by institutional investors. Comparatively, 27.1% of Co-Diagnostics shares are owned by institutional investors. 3.5% of Orthofix Medical shares are owned by insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Orthofix Medical and Co-Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orthofix Medical5.75%1.82%1.20%
Co-Diagnostics53.81%93.48%88.06%

Analyst Ratings

This is a breakdown of recent recommendations for Orthofix Medical and Co-Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orthofix Medical01002.00
Co-Diagnostics01102.50

Orthofix Medical currently has a consensus target price of $39.00, suggesting a potential downside of 9.03%. Co-Diagnostics has a consensus target price of $18.00, suggesting a potential upside of 97.80%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Orthofix Medical.

Risk and Volatility

Orthofix Medical has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -3.3, meaning that its stock price is 430% less volatile than the S&P 500.

Summary

Co-Diagnostics beats Orthofix Medical on 8 of the 14 factors compared between the two stocks.

Surmodics (NASDAQ:SRDX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Surmodics and Co-Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surmodics$94.86 million8.29$1.12 million$0.13439.54
Co-Diagnostics$220,000.001,185.73$-6,200,000.00($0.36)-25.28

Surmodics has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.2% of Surmodics shares are owned by institutional investors. Comparatively, 27.1% of Co-Diagnostics shares are owned by institutional investors. 7.1% of Surmodics shares are owned by insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Surmodics and Co-Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surmodics1.18%1.42%1.12%
Co-Diagnostics53.81%93.48%88.06%

Analyst Recommendations

This is a breakdown of recent ratings for Surmodics and Co-Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surmodics00303.00
Co-Diagnostics01102.50

Surmodics presently has a consensus target price of $69.00, indicating a potential upside of 20.76%. Co-Diagnostics has a consensus target price of $18.00, indicating a potential upside of 97.80%. Given Co-Diagnostics' higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Surmodics.

Volatility and Risk

Surmodics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Co-Diagnostics has a beta of -3.3, meaning that its share price is 430% less volatile than the S&P 500.

Summary

Surmodics beats Co-Diagnostics on 9 of the 14 factors compared between the two stocks.


Co-Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
Soliton logo
SOLY
Soliton
1.1$18.25-0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90-0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73-0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20-0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50-3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79-2.5%$324.97 million$62.66 million-7.61Gap Up
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54-1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62-3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04-3.0%$295.96 million$38.52 million75.13News Coverage
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53-0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82-7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72-0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96-3.6%$159.59 millionN/A-34.80Gap Up
PolyPid logo
PYPD
PolyPid
1.4$9.33-2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44-0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66-1.1%$147.07 million$50.71 million-4.56Gap Up
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20-1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50-0.7%$142.95 million$9.13 million-1.15News Coverage
Gap Up
Beyond Air logo
XAIR
Beyond Air
1.7$5.95-1.8%$121.90 million$1.39 million-3.79
Venus Concept logo
VERO
Venus Concept
1.9$2.24-2.2%$120.90 million$110.41 million-0.67Gap Down
Liquidia logo
LQDA
Liquidia
1.5$2.58-1.9%$111.81 million$8.07 million-1.21Gap Up
Brainsway logo
BWAY
Brainsway
1.3$9.37-0.6%$104.24 million$23.10 million-29.28News Coverage
Pro-Dex logo
PDEX
Pro-Dex
0.7$26.89-0.4%$103.82 million$34.83 million26.97
Nephros logo
NEPH
Nephros
2.0$8.07-3.3%$79.98 million$10.33 million-17.54News Coverage
Gap Up
LENSAR logo
LNSR
LENSAR
1.7$7.02-1.0%$76.75 millionN/A0.00Gap Down
Neovasc logo
NVCN
Neovasc
1.4$1.01-3.0%$67.65 million$2.09 million-0.32Analyst Upgrade
Sensus Healthcare logo
SRTS
Sensus Healthcare
1.3$3.78-0.5%$62.32 million$27.26 million-9.00Gap Down
Motus GI logo
MOTS
Motus GI
1.5$1.27-2.4%$59.37 million$110,000.00-1.79
Delcath Systems logo
DCTH
Delcath Systems
1.8$13.79-1.6%$56.77 million$1.58 million-0.01Analyst Report
STRATA Skin Sciences logo
SSKN
STRATA Skin Sciences
1.5$1.62-1.9%$54.76 million$31.59 million-11.57Gap Down
Sintx Technologies logo
SINT
Sintx Technologies
1.3$1.82-3.3%$44.93 million$690,000.00-0.77
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.